Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3252884 | 0.99 | EGFR (0.46) | EGFRERBB2FGFR1AURKAVCP | |
| SCHEMBL3253485 | 0.87 | EGFR (0.53) | EGFRERBB2FGFR1AURKA | |
| Hydrochloric Acid SCHEMBL3253518 | 0.86 | EGFR (0.52) | EGFRERBB2FGFR1 | |
| SCHEMBL3251095 | 0.80 | AURKA (0.45) | FGFR1AURKAVCPMAP4K4KDR | |
| SCHEMBL7006376 | 0.76 | MERTK (0.38) | EGFRERBB2FLT3GSK3B | |
| SCHEMBL3899412 | 0.74 | EGFR (0.87) | EGFRERBB2 | |
| SCHEMBL3247130 | 0.73 | ADK (0.39) | — | |
| SCHEMBL3244784 | 0.72 | TP53 (0.38) | FLT3PRKCDCLK4 | |
| SCHEMBL3244787 | 0.72 | TP53 (0.38) | FLT3PRKCDCLK4 | |
| SCHEMBL5574155 | 0.70 | AURKA (0.36) | FGFR1AURKAVCPAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | claimed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | claimed |
| EP-1303495-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | Krenitsky Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2002008205-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1303495-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | Krenitsky Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008205-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | BDNF, NTRK2, GAP43 | EGFR 761/4885ERBB2 504/4885FGFR1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.